
    
      This is a Phase III, multicenter, randomized, double-blinded trial designed to evaluate
      Overall survival (OS) of SCT-I10A combined with standard chemotherapy in patients living with
      Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma
    
  